Recursion overhauls pipeline after key drug fails in mid-stage trial
Endpoints News - 05-May-2025With $509M in cash, biotech bets on fewer, stronger programs ahead of 2025 data
Join the club for FREE to access the whole archive and other member benefits.
Biotechnology company combining experimental biology and automation with artificial intelligence.
Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease. Recursion applies causative perturbations to human cells to generate disease models and associated biological image data. Recursion’s rich, relatable database of more than a petabyte of biological images generated in-house on the company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics to radically improve lives. Recursion is headquartered in Salt Lake City.
Visit website: https://www.recursionpharma.com/
Details last updated 07-Jul-2020
With $509M in cash, biotech bets on fewer, stronger programs ahead of 2025 data
This merger aims to deliver quicker results and generate substantial revenue
Including BenevolentAI which already has 24 drug candidates. 98% of big data has only been creat...